Pharmacokinetics linearity [Regulatives / Guidelines]

posted by pjs – India, 2015-05-20 12:25 (3559 d 23:43 ago) – Posting: # 14854
Views: 5,623

Dear all,

What information may be needed to extrapolate linearity for the oral solution dosage form.
  1. Innovator has developed tablet and has established linearity in the dose range e.g. 10-200mg (oral) and 2-10 mg (IV).
  2. Generic oral solution has been available in the strength of 5mg/5ml and 25 mg/5ml.
If we develop oral solution which is Q1 same and Q2 similar (no excipient affecting GI motility/similar to generic). How can we prove linearity for 5mg/5ml strength and get biowaiver?

Drug is BCS class 3

Has been used in the general population for more than 10 years and the submission is for Europe.

Regards,
PJS

Complete thread:

UA Flag
Activity
 Admin contact
23,381 posts in 4,914 threads, 1,662 registered users;
70 visitors (0 registered, 70 guests [including 12 identified bots]).
Forum time: 11:08 CET (Europe/Vienna)

Science is built up with facts, as a house is with stones.
But a collection of facts is no more a science
than a heap of stones is a house.    Henri Poincaré

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5